Drug Discovery Services Market Size, Share & Industry Analysis, By Service Type (Chemistry Services and Biology Services), By Discovery Phase (Target Identification & Validation, Hit Identification, Hit-to-Lead, Lead Optimization, and Others), By Drug Type (Small Molecules and Biologics), By Therapeutic Area (Oncology, Neurological Diseases, Infectious Diseases, Cardiovascular Diseases, and Others), By End User (Pharmaceutical & Biotechnological Companies, Academic & Research Institutes, and Others), and Regional Forecast, 2026-2034

The global drug discovery services market size was valued at USD 19.76 billion in 2025 and is projected to grow from USD 21.11 billion in 2026 to USD 36.22 billion by 2034, exhibiting a CAGR of 7.0% during the forecast period.

Drug discovery services are specialized, outsourced research offerings that help biotechnology and pharmaceutical companies to identify, design, and optimize potential new drugs. The increasing prevalence of chronic conditions, rising outsourcing by pharmaceutical and biotechnology companies, and the expansion of biotechnology pipelines are driving greater adoption of these services in the market. The growing collaborations among academic institutes and CROs are further boosting the adoption of drug discovery services.

• For instance, according to the 2024 statistics published by the World Health Organization (WHO), around 50 million people have epilepsy globally.

The growing focus on expanding service capabilities among companies, including Wuxi AppTec and Charles River Laboratories, is further driving demand for these services in the market.

Drug Discovery Services Market Trends

Increasing Adoption of Digital Tools and Artificial Intelligence is a Key Market Trend

Pharmaceutical and biotechnology companies are focusing on shortening discovery timelines, improving R&D productivity, and minimizing late-stage failure risk, resulting in growing adoption of automation, artificial intelligence, and computational discovery platforms. AI/ML platforms are increasingly being used across hit discovery, target identification, lead optimization, virtual screening, ADMET prediction, drug repurposing, biomarker discovery, and clinical candidate prioritization.

Automation is also improving the discovery services model. Automated liquid handling and assay development, high-throughput screening, automated synthesis, cloud-based data solutions, and computational modeling enable service providers to process huge compound libraries, generate faster biological readouts, and incorporate multi-omics and structural biology data more efficiently.

• For instance, according to 2024 data published by the Food and Drug Administration (FDA), the FDA has received over 300 submissions for drugs and biological products with AI components since 1995.

Market Dynamics

Market Drivers

Download Free sample to learn more about this report.

Increasing Prevalence of Chronic Disorders to Boost Market Growth

The increasing prevalence of chronic conditions, including cardiovascular disorders, cancer, and others, is resulting in the growing demand for innovative drugs and effective therapies, further augmenting the outsourcing of discovery services among pharmaceutical and biotechnology companies, including assay development, lead optimization, biomarker discovery, ADME/Tox studies, and others.

• For instance, according to 2026 data published by the Parkinson’s Foundation, about 1.1 million people are affected by Parkinson’s disease in the U.S.

This, along with a growing demand for personalized drugs and the expansion of healthcare infrastructure, is driving the adoption of these services in the market. Therefore, the factors above, along with the growing focus of key companies on offering novel services, are anticipated to boost the adoption rate of these services, further contributing to the drug discovery services market growth.

Market Restraints

High Cost Associated with Advanced Drug Discovery Technologies to Hinder Market Growth

Advanced drug discovery workflows rely on sophisticated platforms, including automated liquid handlers, high-throughput screening systems, AI-based computational platforms, bioinformatics infrastructure, cryo-electron microscopes, laboratory information management systems, and others.

These advanced technologies require significant upfront capital investment, trained professionals, software licenses, maintenance contracts, validation processes, and data-management infrastructure, which increases the overall cost of the drug discovery setup, making adoption challenging for small and mid-sized CROs, academic spinouts, and emerging biotechnology companies.

• For instance, according to the 2025 statistics published by the University of Alberta, the cost of the Thermo Fisher Titan Krios G4 high-resolution cryo-electron microscope installed at the university was approximately USD 8.0 million.

Market Opportunities

Expansion of Discovery Outsourcing Networks to Create Opportunities

The expansion of drug discovery outsourcing networks across emerging countries presents a major opportunity in the global market. There is a growing development of pharmaceutical and biotechnological R&D infrastructure, contract research organizations, advanced laboratory networks, and preclinical research facilities across countries, including China, India, and others. Additionally, rising healthcare expenditure, expanding drug pipelines, and expanding government initiatives to support biotechnology innovation are driving demand for outsourced discovery services in the region.

• According to 2023 data published by the World Bank Group, India spends 3.34% of its GDP on healthcare.

Market Challenges

Limited Number of CROs in Emerging Countries to Hamper Market Growth

The limited presence of well-established CROs in various emerging nations is a key challenge for the market. Although emerging countries offer benefits such as a large patient population and lower operating costs, many nations are still deprived of a mature ecosystem of specialized contract research organizations with advanced capabilities in medicinal chemistry, target validation, ADME/DMPK studies, high-throughput screening, toxicology, computational biology, translational research, and more. Therefore, the limited number of technically advanced CROs in emerging markets may hamper the adoption of outsourcing services, further impacting the number of clinical trials and thereby limiting market growth.

• For instance, according to data published by the World Health Organization (WHO) in 2025, only 55 clinical trials were conducted in Yemen.

SEGMENTATION ANALYSIS

By Service Type

Increasing Delivery of Compounds Led to Chemistry Services Segmental Dominance

Based on the service type, the market is classified into chemistry services and biology services. Chemistry services are sub-segmented into synthetic chemistry services, analytical chemistry services, and other services. Biology services are sub-segmented into in-vitro profiling, toxicology, and other services.

Chemistry services held the largest revenue share in 2025, owing to their increasing use across almost every stage of small-molecule drug discovery, driving rising demand for outsourcing drug-delivery services among pharmaceutical and biotechnology companies. This, along with the growing delivery of compounds by service providers, is expected to further contribute to the segment growth.

• For instance, according to data published by WuXi Chemistry, the company reported delivering about 420,000 compounds in 2023.

The biology services segment is expected to grow at a CAGR of 7.2% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Discovery Phase

Increasing Approval of Novel Drugs Led to Dominance of Lead Optimization Segment

Based on the discovery phase, the market is segmented into target identification & validation, hit identification, hit-to-lead, lead optimization, and others.

The lead optimization segment dominated the global market, accounting for 26.8% share in 2025.

The growth is driven by outsourcing lead-optimization services to meet the need for integrated chemistry and biology capabilities, resulting in increased approval of novel drugs.

• For instance, according to 2024 statistics published by the Food and Drug Administration (FDA), about 50 novel drugs were approved by CDER in the U.S.

The target identification & validation segment is set to flourish with a growth rate of 7.9% across the forecast period.

By Drug Type

Growing Approval of Small Molecules Boosted Segment Expansion

Based on drug type, the market is segmented into small molecules and biologics.

The small molecules segment dominated the global market in 2025. Segment growth is driven by the rising prevalence of chronic diseases and the advantages of small molecules, leading to increased approval of small-molecule therapies.

• For instance, according to the 2024 statistics published by the American Chemical Society (ACS), 28 small-molecule drugs were approved, accounting for about 56% of new drugs in the U.S.

The biologics segment is set to flourish with a growth rate of 7.2% across the forecast period.

By Therapeutic Area

Increasing Prevalence of Cancer Led to Oncology Segment Dominance

Based on therapeutic area, the market is segmented into oncology, neurological diseases, infectious diseases, cardiovascular diseases, and others.

The oncology segment dominated the market in 2025. The increasing prevalence of cancer, the growing adoption of outsourcing drug discovery services, and the rising number of CROs are driving segment growth. Furthermore, the segment is set to hold a 34.3% share in 2026.

• For instance, according to 2025 data published by the National Cancer Institute (NCI), an estimated 2.0 million cancer cases are projected to occur in the U.S.

Neurological diseases are projected to grow at a 7.4% CAGR during the forecast period.

By End User

Increasing Demand for Innovative Drugs Boosted Pharmaceutical & Biotechnological Companies Segment Growth

Based on end user, the market is divided into pharmaceutical & biotechnological companies, academic & research institutes, and others.

The pharmaceutical & biotechnological companies segment dominated the market in 2025. The increasing demand for innovative drugs and the growing number of pharmaceutical and biotechnological companies, among others, are key factors driving the segment's growth in the market. Furthermore, the segment is set to hold a 77.0% share in 2026.

• For instance, according to 2026 statistics published by Cross River Therapy (CRT), there are approximately 5,000 companies in the U.S.

Academic & research institutes are projected to grow at a 6.1% CAGR during the forecast period.

Drug Discovery Services Market Regional Outlook

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, at USD 7.34 billion, and also led in 2025, with USD 7.83 billion. The growing prevalence of chronic diseases, the rising adoption of outsourcing services, and the increasing adoption of digital tools and automation are contributing to market expansion in the region.

• For instance, according to 2024 statistics published by the Centers for Disease Control & Prevention (CDC), about 1 in 20 adults aged 20 and older have coronary artery disease in the U.S.

U.S. Drug Discovery Services Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 7.46 billion in 2026, accounting for roughly 35.4% of global sales.

Europe

Europe is projected to grow at 6.2% over the coming years, the second-highest among all regions, and reach a valuation of USD 5.72 billion in 2026. The growing prevalence of chronic conditions is likely to support market growth.

U.K. Drug Discovery Services Market

The U.K. market in 2026 is estimated at around USD 1.06 billion, representing roughly 5.0% of global revenues.

Germany Drug Discovery Services Market

Germany’s market is projected to reach approximately USD 1.27 billion in 2026, equivalent to around 6.0% of global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 5.16 billion in 2026 and secure the position of the third-largest region in the market. The growing outsourcing of drug discovery services and increasing healthcare expenditure are likely to support market growth. In the region, India and China are both estimated to reach USD 0.97 billion and USD 1.80 billion, respectively, in 2026.

Japan Drug Discovery Services Market

The Japan market in 2026 is estimated at around USD 0.85 billion, accounting for roughly 4.0% of global revenues. Japan is expected to grow as drug discovery service networks expand in the market.

China Drug Discovery Services Market

China’s market is projected to be one of the largest globally, with 2026 revenues estimated at around USD 1.80 billion, representing roughly 8.5% of global sales.

India Drug Discovery Services Market

The India market size in 2026 is estimated at around USD 0.97 billion, accounting for roughly 4.6% of global revenues.

Latin America and Middle East & Africa  

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market space during the forecast period. The Latin America market is set to reach a valuation of USD 1.05 billion in 2026. The growing number of academic institutions and the rising demand for targeted therapies are accelerating drug discovery, driving market growth in the region. The Middle East & Africa are also anticipated to grow, driven by the increasing number of research institutes and by key service providers expanding their geographic presence in the market. In the Middle East & Africa, the GCC is set to reach a value of USD 0.41 billion in 2026.

South Africa Drug Discovery Services Market

The South Africa market is projected to reach around USD 0.19 billion in 2026, representing roughly 0.9% of global revenues.

Competitive Landscape

Key Industry Players

Increasing Number of Acquisitions among Other Companies to Support Their Dominance

A strong services portfolio, along with a robust focus on strategic initiatives globally, is one of the key factors contributing to these companies' dominance in the market. Wuxi AppTec and Charles River Laboratories were major companies in the market in 2025. Furthermore, the growing focus of key companies on acquisitions and mergers among other players is likely to strengthen their presence, further contributing to the global drug discovery services market share.

• For instance, in January 2026, Charles River Laboratories acquired PathoQuest, a provider of next-generation sequencing (NGS) solutions for the characterization and quality-control testing of biopharmaceutical products, with the aim of strengthening its biologics testing capabilities.

Other key players, including Labcorp, are also growing in the market, primarily due to their increased focus on strengthening their service offerings.

List of Key Drug Discovery Service Companies Profiled

• Charles River Laboratories (U.S.)
• WuXi AppTec (China)
• Labcorp (U.S.)
• Evotec (Germany)
• Eurofins Scientific (Luxembourg)
• Sygnature (U.K.)
• Pharmaron (China)
• Aragen Life Sciences Ltd. (India)
• Sai Life Sciences Limited (India)
• Crown Bioscience (U.S.)

KEY INDUSTRY DEVELOPMENTS

• May 2026: Concept Life Sciences partnered with OpenBench, a company of success-based AI hit discovery, to accelerate hit identification for biotech companies through a fee-for-success model.
• April 2026: Crown Bioscience, a global CRO and JSR Life Sciences company, partnered with Turbine, a virtual biology company, to advance translational oncology research by integrating Turbine’s in silico virtual assays with its tumor organoid assays based on HUB Organoid Technology to increase its brand presence.
• April 2026: Aurigene Pharmaceutical Services Ltd. announced a USD 100.0 million investment plan to accelerate growth across its CRDMO offerings, spanning small molecules, peptides, nutraceuticals, and biologics.
• March 2026: Sai Life Sciences Limited collaborated with Chemical.AI, a technology company specializing in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows.
• March 2026: Medicilon USA Corp. collaborated with BioPartners X to promote innovative drug research and development services. This helped the company to increase its brand presence in the market.
• January 2026: Mabtech, a global life science tools company specializing in advanced immunoassays, collaborated with Sai Life Sciences Limited, an integrated CRDMO, to establish Sai’s Boston laboratory as a co-marketed US execution and demonstration hub for the Mabtech EYRA platform.
• August 2025: Domainex, an integrated drug discovery services company, collaborated with Pharmacelera, a company in AI-based molecular modeling technologies, to support discovery programs focused on transmembrane proteins such as G protein-coupled receptors (GPCRs) and ion channels - critical therapeutic targets for a broad range of diseases.

REPORT COVERAGE

The report provides a detailed global drug discovery services market analysis and focuses on key aspects such as leading companies and market segmentation, including service type, discovery phase, drug type, therapeutic area, and end user. Besides this, the global report offers insights into the market growth trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation